ALKS Alkermes plc

NASDAQ
$49.06

Alkermes plc (ALKS) is expected to report earnings on October 27, 2026, before the market open. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.7% since its last earnings release on July 28, 2026.

Alkermes plc Beat Consensus Estimates, Reaffirms
Tuesday, July 28, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 27
Tuesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.08)
Rev est $466.03M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $49.37

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Alkermes plc

Alkermes PLC is a biotechnology company engaged in developing, manufacturing & commercializing medicines. The Company has a portfolio of commercial drug products & a clinical pipeline of product candidates that address central nervous system disorders.

Sector

Healthcare

Industry

Drug Manufacturers/Other